VivoSeq
Other

Immune Checkpoint Inhibitors

0

Pipeline Programs↗

8

Active Trials↗

2

Companies Involved↗

Immune Checkpoint Inhibitors is an early-stage landscape with 0 programs across 2 companies. The most active players are Sumitomo Pharma America, Inc., Fate Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

0 programs

PreclinicalF

Fate Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

21

clinical trials

Completed7 · 33%
Unknown status5 · 24%
Recruiting3 · 14%
Active, not recruiting3 · 14%
Not yet recruiting2 · 10%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

21 trials

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Recruiting·PPeking University·Phase 2·NCT06580574·38 enrolled
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT06408688·100 enrolled
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Recruiting·FFudan University·Phase 2·NCT04767009·59 enrolled
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Active, not recruiting·IImmunityBio, Inc.·Phase 2·NCT03228667·40 enrolled
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Active, not recruiting·—·N/A·NCT03695952·100 enrolled
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
Active, not recruiting·FFirst Hospital of China Medical University·N/A·NCT06632106·97 enrolled
Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS
Not yet recruiting·JJun Chen, MD·N/A·NCT06902038·33 enrolled
Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases
Not yet recruiting·—·Phase 2·NCT07118566·40 enrolled
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Completed·JJohns Hopkins University·N/A·NCT04898751·2,214 enrolled
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Completed·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 1·NCT02467361·104 enrolled
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04552418·12 enrolled
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
Completed·HHospital Universitario Araba·N/A·NCT03868046·242 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Completed·FFate Therapeutics·Phase 1·NCT03841110·37 enrolled
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT03492242·1,000 enrolled
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy
Completed·TThe Affiliated Hospital of Qingdao University·Phase 1/2·NCT04670107·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)